. To evaluate the safety and tolerance of autologous TCR-T cells in target positive solid tumor patients.~. Preliminary evaluation of objective response rate (ORR) of autologous TCR-T cells in target positive solid tumor patients (such as esophageal cancer, gastric cancer, head and neck cancer, bladder cancer, melanoma, sarcoma, etc.)
. safety and tolerance~. objective response rate